US › Healthcare

Organogenesis Holdings Inc (ORGO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$2.37+1.28%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$37.2M
Revenue YoY
-57.1%
Net profit
$-56.2M
Profit YoY
-198.0%
EPS
$-0.34
EPS estimate
$-0.29
Net margin
-150.9%

EPS came in at -0.34 against a street estimate of -0.29 — a miss of 17.2%.

Key statistics

Market cap
$301.1M
Forward P/E
12.7
P/B
1.25
Book value
$1.90
EPS (TTM)
$-0.12
52-week high
$7.08
52-week low
$2.04
50-day MA
$2.47
200-day MA
$3.45
Beta
1.32

Analyst view

Analysts rate Organogenesis Holdings Inc a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $3.00.

Shareholding

Insiders
47.46%
Institutions
49.35%

Largest institutional holders

FundStake
Morgan Stanley - Brokerage Accounts9.03%
Soleus Capital Management, L.P.7.84%
Vanguard Group Inc3.85%
BlackRock Inc3.81%
First Light Asset Management, LLC2.72%
Vanguard Capital Management, LLC2.25%
Dimensional Fund Advisors, Inc.2.25%
D. E. Shaw & Co LP1.79%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Organogenesis Holdings Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.